Nandrolone phenylpropionate 100 mg/mL

Basic Info

CAS Number	62-90-8
Active Ingredient	Nandrolone (19-nortestosterone), as the decanoate or phenylpropionate ester
Dosage Form	Oil vial
Specification & Packaging	Strength: 100 mg/mL Pack: 1 × 10 mL vial Group: 02 Item No.: 24

Storage & Common Excipients

Storage Conditions	Tightly closed, protected from light, 15–25 °C; follow the label
Common Excipients	Typical oil formulation: castor, peanut or sesame oil, polysorbate 80, benzyl alcohol, benzyl benzoate, edetate disodium; confirm against COA

Product Introduction

Esterified derivatives of 19-nortestosterone, anabolic–androgenic steroids. The reference product Deca-Durabolin is nandrolone decanoate injection; nandrolone phenylpropionate is also a historical long-acting preparation

Therapeutic Use

Historical indications include muscular dystrophy, severe burns/trauma rehabilitation and aplastic anaemia; as an anabolic agent for wasting and post-surgical recovery. Most markets have withdrawn the human indication; research use only

Mode of Action

The 19-nor structure gives relatively higher anabolic versus androgenic activity; has intrinsic progestogenic activity suppressing gonadotropin release; partially aromatises to oestradiol, but less than testosterone

Administration & Monitoring

As prescribed; rule out prostate and breast cancer first; monitor haemoglobin (polycythaemia risk), PSA, lipids, liver function, sexual function and spermatogenesis

Important Safety Information

An anabolic steroid and controlled substance; non-medical use is unlawful. Long-term abuse causes dependence, and post-cessation low testosterone may persist for months

Adverse Reactions

Injection-site reactions; acne, hirsutism, alopecia; testicular atrophy, reduced sperm count and infertility in men; menstrual disturbance and voice deepening in women; raised transaminases, reduced HDL; polycythaemia; mood symptoms (irritability, depression)

Important Risks

Cardiovascular risk (polycythaemia, dyslipidaemia, myocardial hypertrophy), reproductive suppression, hepatotoxicity, gynaecomastia; effects on lipids and coagulation; long-term dependence

Contraindications

Pregnancy and lactation; known or suspected prostate or breast cancer; severe cardiac, hepatic or renal impairment; children and adolescents

Special Populations

Contraindicated in children and adolescents; prostate and cardiovascular assessment in older males; may cause infertility in men of childbearing potential, which must be disclosed in advance

Usage Limitations

Prohibited for performance enhancement (WADA Prohibited List); prescription and controlled-substance handling required; rotate injection sites and use aseptic technique

Anti-Doping Testing

WADA Prohibited List S1.1; targets nandrolone and its 19-NA metabolites (19-norandrosterone/19-norethiocholesterol), detected in urine by LC-MS/MS and GC-C-IRMS

Product Quality Testing

Identification (HPLC/MS), assay and content uniformity, related substances, clarity and particulate matter, fill volume, sterility and endotoxin, residual solvents, stability; COA